Thank you very much;
you're only a step away from
downloading your reports.
Stocks: Insiders Buy at Argos Therapeutics, Biolase, and El Paso Pipeline
Plus, a purchase at Bally Technologies.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Insider Purchases:
  • Pharmstandard International (LON:PHST), a beneficial owner of biopharmaceutical company Argos Therapeutics (NASDAQ:ARGS), bought 1,275,000 shares of company stock for $10,200,000.
  • Richard Kinder, CEO of El Paso Pipeline (NYSE:EPB), which owns and operates interstate natural gas transportation and terminaling facilities, bought 100,000 shares of company stock for $3,003,590.
  • Ramesh Srinivasan, CEO and Director of global gaming company Bally Technologies (NYSE:BYI), bought 15,000 shares of company stock for $1,013,171.
  • Larry Feinberg, a beneficial owner of medical technology company Biolase (NASDAQ:BIOL), bought 2,035,033 shares of company stock for $5,233,379.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JB*
$10,200,000
2
BO
JB*,B
$5,233,379
3
BO
JB*
$4,000,008
4
CB,CEO
B
$3,003,590
5
BO
JB*
$2,197,900
6
BO,SH
JB*
$1,725,276
7
BO
JB*
$1,599,996
8
BO
JB*
$1,266,732
9
CEO,DIR
B
$1,013,171
10
DIR,BO
JB*
$1,000,008

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JS*
$100,519,632
2
COO,DIR
AS
$18,305,756
3
BO
S
$13,650,010
4
BO
JS*
$12,921,000
5
BO
JS*
$10,740,967
6
DIR
AS
$9,978,548
7
DIR
P
S
$9,898,394
8
BO
S
$7,538,792
9
VP
AS
$7,345,804
10
DIR
P
S
$4,937,867

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes


An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
Stocks: Insiders Buy at Argos Therapeutics, Biolase, and El Paso Pipeline
Plus, a purchase at Bally Technologies.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Insider Purchases:
  • Pharmstandard International (LON:PHST), a beneficial owner of biopharmaceutical company Argos Therapeutics (NASDAQ:ARGS), bought 1,275,000 shares of company stock for $10,200,000.
  • Richard Kinder, CEO of El Paso Pipeline (NYSE:EPB), which owns and operates interstate natural gas transportation and terminaling facilities, bought 100,000 shares of company stock for $3,003,590.
  • Ramesh Srinivasan, CEO and Director of global gaming company Bally Technologies (NYSE:BYI), bought 15,000 shares of company stock for $1,013,171.
  • Larry Feinberg, a beneficial owner of medical technology company Biolase (NASDAQ:BIOL), bought 2,035,033 shares of company stock for $5,233,379.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JB*
$10,200,000
2
BO
JB*,B
$5,233,379
3
BO
JB*
$4,000,008
4
CB,CEO
B
$3,003,590
5
BO
JB*
$2,197,900
6
BO,SH
JB*
$1,725,276
7
BO
JB*
$1,599,996
8
BO
JB*
$1,266,732
9
CEO,DIR
B
$1,013,171
10
DIR,BO
JB*
$1,000,008

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JS*
$100,519,632
2
COO,DIR
AS
$18,305,756
3
BO
S
$13,650,010
4
BO
JS*
$12,921,000
5
BO
JS*
$10,740,967
6
DIR
AS
$9,978,548
7
DIR
P
S
$9,898,394
8
BO
S
$7,538,792
9
VP
AS
$7,345,804
10
DIR
P
S
$4,937,867

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes


An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
Daily Recap
Stocks: Insiders Buy at Argos Therapeutics, Biolase, and El Paso Pipeline
Plus, a purchase at Bally Technologies.
Jonathan Moreland    

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.

Insider Purchases:
  • Pharmstandard International (LON:PHST), a beneficial owner of biopharmaceutical company Argos Therapeutics (NASDAQ:ARGS), bought 1,275,000 shares of company stock for $10,200,000.
  • Richard Kinder, CEO of El Paso Pipeline (NYSE:EPB), which owns and operates interstate natural gas transportation and terminaling facilities, bought 100,000 shares of company stock for $3,003,590.
  • Ramesh Srinivasan, CEO and Director of global gaming company Bally Technologies (NYSE:BYI), bought 15,000 shares of company stock for $1,013,171.
  • Larry Feinberg, a beneficial owner of medical technology company Biolase (NASDAQ:BIOL), bought 2,035,033 shares of company stock for $5,233,379.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JB*
$10,200,000
2
BO
JB*,B
$5,233,379
3
BO
JB*
$4,000,008
4
CB,CEO
B
$3,003,590
5
BO
JB*
$2,197,900
6
BO,SH
JB*
$1,725,276
7
BO
JB*
$1,599,996
8
BO
JB*
$1,266,732
9
CEO,DIR
B
$1,013,171
10
DIR,BO
JB*
$1,000,008

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JS*
$100,519,632
2
COO,DIR
AS
$18,305,756
3
BO
S
$13,650,010
4
BO
JS*
$12,921,000
5
BO
JS*
$10,740,967
6
DIR
AS
$9,978,548
7
DIR
P
S
$9,898,394
8
BO
S
$7,538,792
9
VP
AS
$7,345,804
10
DIR
P
S
$4,937,867

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes


An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
< Previous
  • 1
Next >
No positions in stocks mentioned.
EDITOR'S PICKS
 
WHAT'S POPULAR